Revenue Gains, Bold Guidance Lift ADMA Shares
From Yahoo Finance: 2025-05-09 05:37:00
ADMA, a biopharmaceutical company, is gaining popularity with its plasma-derived treatments for immunocompromised patients. Recent regulatory approval for production process enhancement is expected to boost output and overall business growth. Financially, first-quarter fiscal 2025 earnings report showed significant gains in revenue, profits, EBITDA, and net income, with increased guidance for fiscal 2025 and 2026.
ADMA shares are up 24% this year, with Big Money investors betting heavily on its future. Institutional volumes indicate strong investor support, with unusually large volumes in ADMA shares. Health care names are under accumulation, but ADMA stands out with its strong sales and earnings growth, and estimated EPS increase by +40.4% this year.
The stock’s rise is attributed to its strong financial performance, institutional support, and healthy fundamental backdrop. ADMA has been a top-rated stock at MAPsignals, showcasing unusual buy pressure and growing fundamentals. Unusual volumes and big money demand are driving the stock’s upward trajectory, making it a top pick multiple times in the last year.